Wilmington Savings Fund Society FSB Purchases 3,069 Shares of Boston Scientific Co. (NYSE:BSX)

Wilmington Savings Fund Society FSB increased its position in shares of Boston Scientific Co. (NYSE:BSX) by 21.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 17,087 shares of the medical equipment provider’s stock after acquiring an additional 3,069 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Boston Scientific were worth $1,526,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of BSX. Values First Advisors Inc. bought a new position in shares of Boston Scientific in the third quarter worth $28,000. Dunhill Financial LLC grew its position in Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 152 shares in the last quarter. Global Wealth Strategies & Associates increased its stake in Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 250 shares during the last quarter. West Oak Capital LLC purchased a new stake in shares of Boston Scientific in the 4th quarter valued at about $29,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new stake in shares of Boston Scientific during the 3rd quarter valued at about $30,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

BSX stock opened at $105.33 on Monday. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm’s 50-day moving average price is $94.88 and its two-hundred day moving average price is $87.21. The stock has a market capitalization of $155.24 billion, a price-to-earnings ratio of 84.26, a PEG ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 12-month low of $64.39 and a 12-month high of $107.17.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, equities analysts predict that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BSX. Canaccord Genuity Group upped their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Wells Fargo & Company raised their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research report on Thursday. TD Cowen upped their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Raymond James raised their price target on Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a research report on Thursday. Finally, Bank of America upped their price objective on Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $106.00.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now directly owns 39,398 shares of the company’s stock, valued at $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now directly owns 29,308 shares of the company’s stock, valued at $2,660,580.24. This represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,302 shares of company stock worth $4,464,725 over the last quarter. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.